Strategic partnerships Zumutor collaborates with a world class Scientific Advisory Board and has engaged Teiko, Inc. for rapid cytometry panel development, indicating openness to strategic collaborations that can accelerate asset development and open new distribution or co-development channels.

Clinical progression Lead asset ZM008 progressing toward IND filing and Phase 1 trials, signaling near-term opportunities for early access programs, companion diagnostic collaborations, or CRO/CMC support services aligned with regulatory milestones.

Global footprint R&D operations in India with headquarters in Cambridge, MA, presenting a cross‑border engagement path for manufacturing, scale-up partnerships, and regional commercial strategy targeting North America and India markets.

Funding momentum Recent Series A4 funding of $6.2M from notable investors (Accel, Bharat Innovation Fund, Siana Capital) demonstrates investor confidence and may facilitate co‑investment opportunities, grant collaborations, or joint ventures that require synchronized capital timelines.

Immuno-oncology focus ZM008 targets NK cell activation to enhance anti-tumor responses, creating opportunities for sales through related research tools, assay development services, custom antibody discovery partnerships, and collaborations with CROs serving oncology programs.